Profile data is unavailable for this security.
About the company
Tasly Pharmaceutical Group Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The Company's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The Company mainly distributes its products in the domestic market.
- Revenue in CNY (TTM)8.64bn
- Net income in CNY1.10bn
- Incorporated1998
- Employees9.22k
- LocationTasly Pharmaceutical Group Co LtdTasly Modern TCM BuildingNo. 2, Pujihe East RoadBeichen DistrictTIANJIN 300410ChinaCHN
- Phone+86 2 226736999
- Fax+86 2 226736721
- Websitehttps://www.taslypharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chongqing Taiji Industry Group Co Ltd | 15.40bn | 834.00m | 15.80bn | 12.59k | 18.95 | 4.08 | -- | 1.03 | 1.50 | 1.50 | 27.66 | 6.95 | 1.03 | 3.15 | 5.84 | 1,223,535.00 | 5.77 | 0.7814 | 17.83 | 2.35 | 46.14 | 44.03 | 5.62 | 0.8498 | 0.5315 | 6.12 | 0.5393 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
| BrightGene Bio-Medical Technology Co Ltd | 1.21bn | 195.77m | 15.88bn | 1.16k | 82.30 | 6.54 | -- | 13.08 | 0.4569 | 0.4569 | 2.87 | 5.75 | 0.2463 | 1.69 | 4.43 | 1,051,700.00 | 3.43 | 6.53 | 4.29 | 7.93 | 54.92 | 56.93 | 13.93 | 19.90 | 1.45 | 4.86 | 0.4787 | 29.31 | 15.94 | 23.68 | -15.51 | 22.56 | 29.13 | -- |
| Tonghua Dongbao Pharmaceutical Co Ltd | 3.00bn | 1.13bn | 16.31bn | 3.20k | 14.48 | 2.21 | -- | 5.43 | 0.5682 | 0.5682 | 1.51 | 3.73 | 0.403 | 0.8622 | 4.57 | 939,125.30 | 15.20 | 18.68 | 15.84 | 19.68 | 79.89 | 78.73 | 37.71 | 39.20 | 5.04 | -- | 0.03 | 41.73 | 10.69 | 2.69 | -26.17 | 6.85 | -14.75 | 4.56 |
| Shandong Buchang Pharmaceuticals Co Ltd | 12.37bn | -22.28m | 16.91bn | 8.31k | -- | 1.46 | -- | 1.37 | -0.0202 | -0.0202 | 11.18 | 10.46 | 0.5678 | 1.00 | 9.58 | 1,488,478.00 | -0.9013 | 3.26 | -1.30 | 4.72 | 64.05 | 74.71 | -1.59 | 4.85 | 0.5348 | 2.34 | 0.2522 | 121.01 | -11.41 | -0.6219 | 120.85 | -29.93 | -16.56 | -36.72 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.63bn | -344.58m | 19.08bn | 1.45k | -- | 3.18 | -- | 5.26 | -0.2727 | -0.2727 | 2.30 | 3.71 | 0.3561 | 0.4354 | 3.35 | 2,500,466.00 | -3.38 | 8.97 | -4.83 | 13.15 | 43.57 | 45.59 | -9.50 | 20.12 | 1.15 | -- | 0.3129 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Tasly Pharmaceutical Group Co Ltd | 8.64bn | 1.10bn | 19.27bn | 9.22k | 17.57 | 1.52 | -- | 2.23 | 0.7342 | 0.7342 | 5.77 | 8.47 | 0.4899 | 1.72 | 10.80 | 937,046.80 | 5.93 | 5.47 | 7.21 | 7.25 | 65.67 | 48.42 | 12.11 | 8.94 | 2.73 | 5.91 | 0.2083 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| China Resources Dubl-Crne Phrmctl Co Ltd | 10.32bn | 1.38bn | 19.73bn | 12.27k | 14.15 | 1.69 | -- | 1.91 | 1.34 | 1.34 | 10.07 | 11.24 | 0.6781 | 2.85 | 5.82 | 841,054.60 | 8.87 | 8.58 | 11.67 | 11.21 | 54.25 | 58.19 | 13.08 | 11.98 | 2.15 | -- | 0.0249 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Joincare Pharmaceutical Group Ind. Co. | 16.43bn | 1.42bn | 20.50bn | 14.37k | 14.25 | 1.43 | -- | 1.25 | 0.7676 | 0.7676 | 8.86 | 7.63 | 0.4522 | 2.36 | 5.57 | 1,143,551.00 | 7.98 | 8.46 | 16.51 | 18.84 | 61.23 | 62.72 | 17.64 | 17.00 | 2.11 | -- | 0.2247 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
| Xiamen Amoytop Biotech Co Ltd | 2.23bn | 600.08m | 22.08bn | 1.96k | 36.80 | 11.01 | -- | 9.92 | 1.48 | 1.48 | 5.47 | 4.93 | 1.04 | 0.8541 | 6.70 | 1,135,877.00 | 28.09 | 17.96 | 32.72 | 21.02 | 93.17 | 90.48 | 26.95 | 19.17 | 3.22 | -- | 0.0037 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
Data as of Jul 05 2024. Currency figures normalised to Tasly Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
5.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 30 Sep 2023 | 23.42m | 1.56% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 9.41m | 0.63% |
| Da Cheng Fund Management Co., Ltd.as of 30 Sep 2023 | 8.21m | 0.55% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 6.78m | 0.45% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 6.28m | 0.42% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 6.05m | 0.40% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 5.99m | 0.40% |
| First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 5.76m | 0.38% |
| Great Wall Fund Management Co., Ltd.as of 31 Dec 2023 | 4.73m | 0.32% |
| Cinda Fund Management Co. Ltd.as of 31 Dec 2023 | 4.45m | 0.30% |
More ▼
Data from 31 Dec 2023 - 27 Jun 2024Source: FactSet Research Systems Inc.
